News|Articles|December 29, 2025

The Top 5 Most-Read Soft Tissue Sarcoma Articles of 2025

Author(s)Rose McNulty
Fact checked by: Julia Bonavitacola
Listen
0:00 / 0:00

Key Takeaways

  • Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy.
  • Blood-based markers such as NLR and ctDNA may refine STS treatment, improving patient selection for therapies and reducing unnecessary toxicities.
SHOW MORE

The most-read articles focused on soft tissue sarcoma research, including innovative biomarkers, treatment strategies, and multidisciplinary care challenges.

This year’s top soft tissue sarcoma (STS) articles highlight a multifaceted push to better understand, diagnose, and manage this rare and heterogeneous group of cancers. Recurring themes include the promise of novel biomarkers for improving diagnosis and guiding therapy, the clinical complexity and unpredictable behavior of STS, and the balancing of treatment efficacy with quality of life and complications.

Together, these pieces highlight both the progress and ongoing challenges in sarcoma care, from bench science and biomarker exploration to real-world clinical decision-making and multidisciplinary care considerations.

Here are the top 5 soft tissue sarcoma articles of 2025:


5. New Biomarkers Show Promise in Improving Diagnosis, Prognosis in Uterine Sarcoma

Circulating biomarkers could transform how uterine sarcoma—a rare soft tissue sarcoma subtype—is diagnosed and prognosticated. Researchers found that growth differentiation factor-15 (GDF15) and osteopontin (OPN) levels in the blood accurately distinguished uterine sarcoma from benign leiomyomas, outperforming traditional markers such as LDH and CA125. Elevated GDF15 was also linked with worse progression-free survival, suggesting it could help guide treatment decisions. These findings, although preliminary, suggest noninvasive tests could help clinicians identify sarcoma early and tailor therapy more effectively.

Read the full article.

4. Blood-Based Biomarkers Could Reshape Soft Tissue Sarcoma Therapy

Another study explored blood-based markers to refine STS treatment. Traditional predictive tools like PD-L1 or tumor mutation burden have limited utility in sarcomas, prompting interest in alternative signals such as neutrophil-to-lymphocyte ratio (NLR) and circulating tumor DNA (ctDNA). Early data suggest low NLR might be associated with better response to targeted therapies like pazopanib, and ctDNA levels might correlate with response to immune checkpoint inhibitors in some sarcoma subtypes. Given STS’s diversity—more than 80 histologies—the ability to better select patients for specific therapies could improve outcomes and spare non-responders unnecessary toxicities. The article calls for more research to validate these biomarkers and integrate them into clinical practice.

Read the full article.

3. Rare Case of Soft Tissue Sarcoma Spreading to the Heart Highlights Diagnostic, Therapeutic Challenges

A rare case saw synovial sarcoma metastasizing to the heart, illustrating the diagnostic challenges posed by atypical disease spread. The patient presented with neurologic symptoms that initially masked the underlying cardiac involvement. Advanced imaging revealed a left atrial mass, which was surgically removed and followed by systemic therapy. The case emphasizes the importance of multidisciplinary collaboration and vigilance for unusual metastatic patterns, particularly in patients with prior sarcoma diagnoses and unexplained cardiovascular or neurologic symptoms.

Read the full article.

2. Mixed Outcomes From Multidisciplinary Sarcoma Clinic

An evaluation of a multidisciplinary sarcoma clinic showed that although patients were more likely to receive multimodal therapy, treatment initiation was not significantly faster compared with standard care. The findings suggest that specialized clinics may influence treatment planning and complexity but do not automatically overcome logistical and social barriers, such as travel distance or additional diagnostic requirements. The study underscores that although multidisciplinary care remains a cornerstone of sarcoma management, additional system-level solutions are needed to improve timeliness and access for patients.

Read the full article.

1. Radiotherapy Raises Risk of Complications After Limb STS Surgery

An analysis published in the International Wound Journal examined outcomes for patients undergoing limb soft tissue sarcoma surgery with or without radiotherapy. Results showed higher rates of wound complications, longer hospital stays, and extended follow-up care among those receiving radiotherapy. Although radiotherapy plays a key role in improving local tumor control, the findings highlighted the need to carefully weigh benefits against postoperative risks and reinforced the importance of individualized treatment planning and strategies to mitigate complications while preserving oncologic outcomes.

Read the full article.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo